Papers
2
Total Citations
30
H-Index
2
About
Daniele Raggi is a prominent urologic oncologist whose research focuses on optimizing surgical and oncologic outcomes for patients with kidney and bladder cancers. His work centers on two key areas: the impact of frailty on surgical outcomes in renal cell carcinoma, and the evolving role of neoadjuvant therapies for muscle-invasive bladder cancer. In his landmark 2022 study on partial nephrectomy, Raggi demonstrated that preoperative frailty status significantly predicts postoperative complications, functional decline, and long-term oncologic outcomes—a finding that has garnered 17 citations and is reshaping preoperative risk stratification. His 2020 paper critically examined the paradigm shift toward neoadjuvant chemotherapy and immunotherapy for clinical T2N0 bladder cancer, arguing that current evidence supports moving beyond traditional cystectomy-first approaches. With 13 citations, this work has influenced clinical trial design and treatment guidelines. Raggi’s contributions bridge the gap between surgical technique and personalized medicine, offering actionable insights for clinicians managing complex urologic cancers. His research is particularly notable for integrating geriatric assessment tools into oncologic surgery, a forward-thinking approach that addresses the needs of an aging patient population.
Research Focus
Key Achievements
Top Papers
- 1
- 2